Key Takeaways:
- Pfizer currently offers a high 6.7% forward dividend yield.
- The dividend appears sustainable, though near-term earnings volatility may create some pressure on the company’s dividend.
- Long-term dividend growth is likely to be low, unless Pfizer is able to refresh its drug pipeline and rebuild post-COVID momentum.
- Get accurate financial data on over 100,000 global stocks for free on TIKR >>>
Pfizer became a household name during the pandemic, but the company has long been a staple in dividend portfolios.
It’s a big, established pharmaceutical player with a history of rewarding shareholders, and right now, it’s offering a very high dividend yield.
With high interest rates and some investors looking to play it safe, Pfizer’s mix of stability, healthcare exposure, and income potential makes it a stock worth watching.
The business may be in a transition phase, but for income-focused investors, the dividend alone might be reason enough to take a closer look.
1: Dividend Yield
Pfizer’s current dividend yield is one of the more generous payouts you’ll find among large-cap healthcare stocks.
Today, it’s higher than its historical average, partly because the stock has pulled back recently. That means the dividend now represents a larger return compared to the share price.
For income investors, that’s often a signal to pay attention. While some companies with high yields raise red flags, Pfizer’s long track record and global presence give investors more confidence that this isn’t just a temporary spike in dividends, but it could be a good opportunity for long-term dividend income.
Find high-yield dividend stocks that are even better than Pfizer >>>
2: Dividend Safety
The good news is that Pfizer still generates plenty of cash to support its dividend.
The company has a long history of paying dividends through economic cycles, and even with earnings down post-COVID, it hasn’t shown signs of backing off those payments.
That said, there is a little uncertainty ahead. Management will need to lean on its pipeline and upcoming drug launches to keep profits steady.
As of now, the dividend looks safe, but it’s something worth monitoring if the pipeline underperforms.
Analyze stocks like Pfizer quicker with TIKR >>>
3: Dividend Growth Potential
Pfizer has a decent track record of raising its dividend over time, although the growth rate hasn’t been as aggressive as some other sectors.
It’s been more of a steady, reliable increaser than a flashy one. That approach makes sense for a company in a highly regulated, research-heavy business.
Looking forward, dividend growth could return to a more comfortable pace if the company successfully launches new treatments and rebuilds its post-pandemic earnings base.
Until then, expect more of a slow-and-steady path rather than big hikes.
Access up to 5 years of analyst forecasts for Pfizer on TIKR >>>
TIKR Takeaway
Pfizer looks like a strong option for long-term investors who value income, as long as they’re comfortable with some short-term earnings uncertainty.
The TIKR Terminal offers industry-leading financial data on over 100,000 stocks and was built for investors who think of buying stocks as buying a piece of a business.
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
